Latest News

TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results

TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials

TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements

Latest Financial Results

FY 2022

Fiscal Year Ended December 31, 2022

Latest Annual Filing

For Fiscal Year Ending December 31, 2022

Company Overview

We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to develop and commercialize innovative cell-based products and to treat disease, improve patient health and Quality of Life.

TC BioPharm (TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease.

IR Contacts


TC BioPharm Limited
Maxim 1
2 Parklands Way
Holytown, Motherwell ML1 4WR
United Kingdom
T: +44 (0) 141 433 7557

Investor Relations

Transfer Agent

Computershare Investor Services PLC